Table 3.
MAPK Inhibitor and Immunotherapy Combinations Under Investigation
| Categories | Study Drugs | Population | Phase | Outcomes in CRC | Trial Identifier |
|---|---|---|---|---|---|
| EGFRi + PD-L1i + Chemotherapy | Cetuximab + Avelumab + FOLFOX |
RAS/BRAF WT mCRC |
II | ORR 79.5% | AVETUX-CRC: NCT03174405 |
| BRAFi + MEKi + PD-1i | Dabrafenib + Trametinib + Spartalizumab | BRAF V600E-mutated mCRC | II | Results pending | NCT03668431 |
| MEKi + PD-1i ± Chemotherapy | Binimetinib + Pembrolizumab ± Chemotherapy | pMMR/MSS mCRC |
Ib | Results pending | KEYNOTE-651: NCT03374254 |
| BRAFi + EGFRi + PD-1i | Encorafenib + Cetuximab + Nivolumab | pMMR/MSS and BRAF V600E-mutated unresectable or mCRC | I/II | Results pending | NCT04017650 |
| BRAFi + MEKi + PD-1i | Encorafenib + Binimetinib + Nivolumab | pMMR/MSS and BRAF V600E-mutated mCRC | I/II | Results pending | NCT04044430 |
Abbreviations: BRAFi, BRAF inhibitor; EGFRi, EGFR inhibitor; MEKi, MEK inhibitor; ORR, overall response rate; PD-1i, PD-1 inhibitor; PD-L1i, PD-ligand 1 inhibitor; WT, wild type.